The association between baseline steroids administered for cancer-related indications and worse clinical outcomes with PD-1/PD-L1 checkpoint inhibitors is supported by other studies showing a significantly higher risk of disease progression and death in patients receiving steroids due to palliative reasons [59,62]. The gene discussed is PDCD1; the disease is cancer.